Integrated Filing — IndAS



General information about company

Scrip Code 532649
NSE Symbol NECLIFE
MSEI Symbol NOTLISTED
ISIN INE023H01027
Name of company Nectar Lifesciences Limited
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2026
Date of end of financial year 31-03-2027
Date of board meeting when results were approved 14-08-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 10-08-2026
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter First quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended
Segment Reporting Single segment
Description of single segment Pharmaceutical Business Segment
Start date and time of board meeting 14-08-2026   19:30:00
End date and time of board meeting 14-08-2026   20:35:00
Whether cash flow statement is applicable on company
Type of cash flow statement
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? No
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
There is no default by the Company on its loans. The Company has not issued any debt securities.



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2026 01-04-2026
B Date of end of reporting period 30-06-2026 30-06-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Standalone Standalone
1 Income
Revenue from operations 1.45 1.45
Other income 628.02 628.02
Total income 629.47 629.47
2 Expenses
(a) Cost of materials consumed 0.00 0.00
(b) Purchases of stock-in-trade 2.75 2.75
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade (1.38) (1.38)
(d) Employee benefit expense 103.28 103.28
(e) Finance costs 15.69 15.69
(f) Depreciation, depletion and amortisation expense 11.06 11.06
(f) Other Expenses
1 Other Expenses 2,663.56 2,663.56
Total other expenses 2,663.56 2,663.56
Total expenses 2,794.96 2,794.96
3 Total profit before exceptional items and tax (2,165.49) (2,165.49)
4 Exceptional items 0.00 0.00
5 Total profit before tax (2,165.49) (2,165.49)
6 Tax expense
7 Current tax 0.00 0.00
8 Deferred tax (819.87) (819.87)
9 Total tax expenses (819.87) (819.87)
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations (1,345.62) (1,345.62)
12 Profit (loss) from discontinued operations before tax 49.35 49.35
13 Tax expense of discontinued operations 17.25 17.25
14 Net profit (loss) from discontinued operation after tax 32.10 32.10
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0.00 0.00
16 Total profit (loss) for period (1,313.52) (1,313.52)
17 Other comprehensive income net of taxes 0.00 0.00
18 Total Comprehensive Income for the period (1,313.52) (1,313.52)
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 1,942.61 1,942.61
Face value of equity share capital 1 1
27 Details of debt securities
22 Reserves excluding revaluation reserve
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations -0.69 -0.69
Diluted earnings (loss) per share from continuing operations -0.69 -0.69
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0.02 0.02
Diluted earnings (loss) per share from discontinued operations 0.02 0.02
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations -0.67 -0.67
Diluted earnings (loss) per share from continuing and discontinued operations -0.67 -0.67
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results

Textual Information(1) Notes 1. The above financial results were reviewed by Audit Committee on August 14, 2026, and approved by the Board in its meeting held on August 14, 2026. The statutory auditors of the Company have conducted a “Limited Review” of the above standalone and consolidated unaudited financial results for the quarter ended on June 30, 2026. 2. The Company is exclusively in the pharmaceutical business segment. 3. Previous period’s figures have been regrouped and reclassified wherever necessary to make them comparable with current period. 4. The figures of the last quarter for the previous financial year i.e. March 31, 2026, are the balancing figures between the audited figure in respect of the full previous financial year ended March 31, 2026, and the unaudited published year to date figures up to the third quarter ended December 31, 2025, which was subject to limited review and not audit. 5. The Company has two wholly owned subsidiaries with the following details: - a) Neclife PT, Unipessoal LDA, remained inoperative during the period. b) Avensis Exports Private Limited (“AEPL”). 6. The Company is Not a Large Corporate as per the framework provided in the SEBI Circular dated October 19, 2023, on Fund raising by issuance of debt securities by Large Entities. 7. Going Concern During the previous financial year, the Company had sold a substantial part of its existing business operations by way of slump sale and incurred losses. The transaction had resulted in significant liquidity, and the Company, after discharging all its debts, continues to possess adequate cash and liquid resources to meet its obligations, if any. Further, the Company had amended its object clause to undertake activities in the real estate sector and is currently evaluating the various projects under the revised business framework. In furtherance of this objective, the Company had also acquired AEPL as its wholly owned subsidiary. Considering the Company’s solvent financial position and availability of funds, the Board believes that the Company will continue to operate as a going concern for the foreseeable future. Accordingly, the financial results have been prepared on a going concern basis. 8. Material Transactions A. Assets Classified as Held for Sale a. Capsule Business (EHGC) The Company had entered into a Business Transfer Agreement (“Capsule BTA”) dated December 20, 2025, with Capnest Health Care Private Limited (“Capnest”) for the slump sale of its Empty Hard Gelatin Capsule business located at Village Bhatoli Kalan, Pargana Dharmpur, Tehsil Baddi, District Solan, Himachal Pradesh (“Capsule Business”), on a going concern basis, for a consideration of Rs.1,990.00 lakhs, including transfer of related receivables and payables/creditors, subject to working capital adjustments specified in the Capsule BTA and approval under Section 118 of the Himachal Pradesh Tenancy and Land Reforms Act, 1972. The transaction shall be completed in accordance with the terms set out in the Capsule BTA. b. Other Assets The Company is also evaluating the monetization of the following assets with the objective of optimizing non-core assets and further strengthening its liquidity position: (i) Jammu Unit: Fixed assets pertaining to the Company’s Jammu unit, which has remained inoperative. The same has been disposed of in the subsequent quarter, and the impact thereof will be disclosed accordingly. (ii) Land near Garhshankar, Punjab: Vacant land situated near Garhshankar, Punjab. A portion of the said land has already been sold in the current quarter, and the balance is expected to be sold by the end of this financial year. Accordingly, the results relating to the above disposed businesses/assets have been disclosed as discontinued operations in accordance with Ind AS 105. Further, in the audited standalone financial results, the net result of “Capsule Business” has been disclosed separately as discontinued operation as required by Indian Accounting Standard (Ind AS) 105 – Asset Held for Sale and Discontinued Operations and Schedule Ill to the Companies Act, 2013. Consequently, the Company's Statement of Profit and Loss for the period ended June 30, 2026, pertains to its continuing operations only and for that purpose the results for the other reporting periods i.e., March 31, 2026, and June 30, 2025, have been restated accordingly. Standalone Operations relating to the “Capsule Business” in respect of total income, total expenses and tax are being disclosed separately as Discontinued operations as part of the results below: Rs. in lakhs S. No. Particulars Quarter Ended Year Ended 30-Jun-26 31-Mar-26 30-Jun-25 31-Mar-26 Restated Unaudited Audited Unaudited Audited 1 Revenue from operations 574.14 571.35 28,066.50 40,138.43 2 Other income 5.45 0.18 4.68 1,221.82 3 Total expenses 530.24 7,892.12 37,760.15 95,125.77 4 Profit before tax 49.35 (7,320.59) (9,688.97) (53,765.51) 5 Exceptional item (Gain on slump sale) - - - 16,337.32 6 Tax expenses 17.25 (4,249.39) (3,357.08) (13,873.82) 7 Net profit after tax 32.10 (3,071.20) (6,331.89) (23,554.37) 9. Pursuant to the approvals granted by the Board, the Company deployed certain surplus funds in mutual fund, ETF and equity instruments during the year. Subsequently, volatility in the financial markets arising from prevailing market conditions and geopolitical developments adversely impacted the value of such investments, resulting in a loss of Rs.2,513.29 lakhs. The resultant impact has been recognized in the Statement of Profit and Loss in accordance with Ind AS 109 – Financial Instruments.



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2026 01-04-2026
Date of end of reporting period 30-06-2026 30-06-2026
Whether results are audited or unaudited Unaudited Unaudited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2026 01-04-2026
B Date of end of reporting period 30-06-2026 30-06-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
Total Amount of items that will not be reclassified to profit and loss
2 Income tax relating to items that will not be reclassified to profit or loss
3 Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4 Income tax relating to items that will be reclassified to profit or loss
5 Total Other comprehensive income





Details of Impact of Audit Qualification

Amount in (Lakhs)

Whether results are audited or unaudited Unaudited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 Deepak Jindal & Co. Yes 31-05-2027